Sec Form 13G Filing - Soleus Capital Master Fund, L.P. filing for - 2026-02-19

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus Capital Master Fund, L.P. ("Master Fund"). Soleus Capital, LLC ("Soleus Capital") is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, Soleus Capital Management, L.P. ("SCM") is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of the common stock, par value $0.0001 per share ("Common Stock"), of Immunic, Inc. (the "Issuer"), issuable upon the exercise of pre-funded warrants held by Master Fund (the "PFWs"), which PFWs are presently exercisable at an exercise price of $0.0001 per share of Common Stock, and (y) 1,146,000 shares of Common Stock issuable upon the exercise of warrants held by Master Fund that are exercisable on the first trading date following the date on which the Issuer consummates the reverse split of its Common Stock contemplated by that certain Securities Purchase Agreement dated as of February 12, 2026 by and among the Issuer and the investors party thereto at an exercise price of $0.873220 per share of Common Stock (such warrants, the "Common Warrants"). (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as reported on the cover of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025 (the "Form 10-Q").


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of Common Stock issuable upon the exercise of the PFWs and (y) 1,146,000 shares of Common Stock issuable upon the exercise of the Common Warrants. (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of Common Stock issuable upon the exercise of the PFWs and (y) 1,146,000 shares of Common Stock issuable upon the exercise of the Common Warrants. (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of Common Stock issuable upon the exercise of the PFWs and (y) 1,146,000 shares of Common Stock issuable upon the exercise of the Common Warrants. (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaim s beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of Common Stock issuable upon the exercise of the PFWs and (y) 1,146,000 shares of Common Stock issuable upon the exercise of the Common Warrants. (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons \s the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes (x) 1,146,000 shares of Common Stock issuable upon the exercise of the PFWs and (y) 1,146,000 shares of Common Stock issuable upon the exercise of the Common Warrants. (3) The percentage set forth in row 11 is calculated based upon 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as set forth on the cover of the Form 10-Q.


SCHEDULE 13G


 
Soleus Capital Master Fund, L.P.
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026
 
Soleus Capital, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026
 
Soleus Capital Group, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026
 
Soleus Capital Management, L.P.
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026
 
Soleus GP, LLC
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026
 
Guy Levy
 
Signature:/s/ Guy Levy
Name/Title:Guy Levy/Managing Member
Date:02/19/2026

Comments accompanying signature:  Exhibit 99.A - Joint Filing Agreement
primary_doc.xml